NewAmsterdam Pharma Company Investor Relations Material
Latest events
Study Update
NewAmsterdam Pharma Company
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from NewAmsterdam Pharma Company N.V.
Access all reports
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company based in the Netherlands, focusing on the development of oral and non-statin medicines for patients at high risk of cardiovascular disease. Its leading product candidate is obicetrapib, a next-generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, currently in various stages of clinical trials. The company's mission is aimed at improving patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated, with a significant focus on creating a potent, cost-effective, and convenient LDL-lowering therapy. The company is headquartered in Naarden, the Netherlands, and its shares are listed on the Nasdaq.
Key slides for NewAmsterdam Pharma Company N.V.
Corporate Presentation
NewAmsterdam Pharma Company N.V.
Study Update
NewAmsterdam Pharma Company N.V.
Latest articles
Timeless Timepieces: The Rolex Story
A comprehensive overview of how Rolex went from a small upstart to one of the most famous and respected brands in the world.
20 Sep 2024
Cristiano Amon: Qualcomm's 5G Specialist CEO
Cristiano Amon, Qualcomm CEO, has spent two decades at the company while taking on several roles, developing both technical and business expertise.
16 Sep 2024
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
Ticker symbol
NAMS
Country
🇺🇸 United States